Aurora News
Portfolio Company News
Metabolon Moves to New Location
Metabolon moves to new location and brings new state–of-the-art metabolomic technology platform online

DURHAM, NC - 4/26/04– Metabolon, Inc. today announced that it has moved to its new office location at Alexandria Technology Center - Alston and has the company's metabolomic technology platform up and fully functioning.

“Our new state-of-the-art facilities have given us the space to install new high end and very sensitive equipment which will enable Metabolon to deliver the full potential of metabolomics as a tool to accelerate drug discovery and development for life science companies,” says John Ryals, President and CEO. Prior to moving to its new facilities, Metabolon occupied space in the BD Technologies incubator and began the move to the new location in mid-February.

Based on the new facilities and new equipment, Metabolon is moving quickly to further its research in ALS (Lou Gehrig's Disease), Alzheimer's and Parkinson's Disease. In addition, Metabolon is working with various academic centers and pharmaceutical companies to assist them in Metabolomics Research.

“This is an exciting time for Metabolon,” according to Reid Tripp, VP, Business Development. “We are having a multitude of discussions with government agencies, academic centers and pharmaceutical companies on how we can work together in Metabolomics. In fact, we already have agreements on several of these projects. In addition to the ALSA grant already announced, we look forward to being able to announce additional new customers and collaborations in the near future.”

“It is reassuring to see how quickly people in the life science community are understanding what we are trying to accomplish and how it will be immensely beneficial to their drug discovery and development process,” says Ryals.

About Metabolon:
Metabolon is a leader in the application of metabolomics, a powerful and new scientific approach for the discovery and development of drugs and the early diagnosis of disease states. Seasoned and successful entrepreneurs, as well as scientific pioneers, make up Metabolon's executive management team and boards.

Metabolon's patent-pending technology is poised to dramatically impact drug discovery and development processes by accurately measuring the spectrum of biochemical changes and mapping these changes to metabolic pathways. Metabolon's technology can identify safer compounds for development, shorten the time for drugs to get to market and identify diagnostic markers for earlier disease detection.

Metabolon's institutional investors include The Aurora Funds, The Trelys Funds and Alexandria Real Estate Equities. For additional information, visit .

Back to Portfolio News